Inflammation-related proteins

Inflammation-related proteins represent a vast and heterogeneous array of molecular species, including cytokines, chemokines, enzymes, and receptors, that coordinate the body's response to noxious stimuli such as pathogens or tissue injury (StatPearls, 2023). Key members of this group include Tumor Necrosis Factor-alpha (TNF-α), Interleukin-6 (IL-6), and Cyclooxygenase-2 (COX-2), which serve as critical nodes in signaling cascades that promote vasodilation, vascular permeability, and immune cell recruitment (PubMed, 2021). While essential for acute host defense and tissue repair, the persistent or dysregulated activation of these proteins is a primary driver of chronic inflammatory diseases, including rheumatoid arthritis, psoriasis, and Crohn's disease (NIH, 2022). Therapeutic strategies in modern medicine often focus on the highly specific inhibition of individual proteins within this class, such as the use of monoclonal antibodies to neutralize cytokines or small molecules to inhibit enzymatic activity. Because this term describes a broad functional group rather than a single molecular entity, it is considered a classification category rather than a specific therapeutic target for drug discovery.

Other names

Inflammatory mediatorsPro-inflammatory proteinsAcute phase reactantsInflammatory cytokinesInflammatory markers

Inhibition of cyclooxygenase enzymes (COX-1/COX-2), neutralization of pro-inflammatory cytokines (e.g., TNF, IL-1, IL-6), antagonism of cytokine receptors, and modulation of intracellular inflammatory signaling pathways such as NF-κB or JAK/STAT (PubChem, 2024).